Researchers have made progress in developing a new nasal spray, INNA-051, designed to enhance the body’s natural defenses against respiratory viruses. This innovative treatment aims to help people, especially those at higher risk, respond more effectively to infections like the flu, RSV, and coronaviruses. INNA-051 is administered as a dry powder nasal spray once a week and works by priming the immune system in the nose, where many viruses enter the body.

This treatment could significantly benefit individuals living in crowded environments, such as university students, military personnel, and childcare workers, who face a higher risk of respiratory infections. The initial phase of the study involved 200 participants and showed no safety concerns, suggesting that INNA-051 could help reduce the severity and duration of infections for those at risk. If successful, this could lead to fewer complications and better overall health for people who are vulnerable to severe illness.

The research is currently in the early stages, having just completed Part A of a Phase IIa clinical trial. While the results are promising, they are not yet definitive. The next phase will involve a larger group of 900 participants and will assess the treatment over three months during the upcoming respiratory virus season. This means that while there is hope for INNA-051 as a new preventive measure, further studies are needed to confirm its effectiveness and safety in a broader population.

Source: globenewswire.com